Inhibitors affect approximately 30% of patients with severe hemophilia A. In addition to substantial treatment and medical costs, patients with hemophilia who have inhibitors are twice as likely to be hospitalized for a bleeding complication. This educational activity addresses risk factors for inhibitor development, testing and monitoring strategies, the role of immune tolerance induction, and the use of bypassing agents in the setting of an inhibitor.
Jordan A. Shavit, M.D., Ph.D. Medical Oncologist, Sarcoma Oncology Center Santa Monica, CA Medical Advisor, Hemophilia Foundation of Southern California Pasadena, CA Medical Director, Orthopaedic Hemophilia Treatment Center, Los Angeles, CA
Doris Quon, MD, PhD. Associate Professor of Pediatrics Division of Pediatric Hematology/Oncology, University of Michigan Medical School CS Mott Children’s Hospital, Ann Arbor, MI
Click here to view this activity: